Adam Pyrzak, MD
Gynecologic Oncology · Atlanta, GANPI 1164859955
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,828 of the $116,451 with a category attached, or 63.4%. Eisai Inc. accounts for 74.4% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $79,046, more than ten times the $229 reported in 2019. Among gynecologic oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $677.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$87K
- Merck$21K
- Johnson & Johnson$4K
- Medical Device Business Services, Inc.$1K
- Intuitive Surgical$1K
- AstraZeneca$730
- plus $1K from 11 others
What the payments were for
- Consulting fees$22,38919%
- Speaking & faculty fees$73,82863%
- Travel & lodging$14,33312%
- Food & beverage$4,8594%
- Education$1,0441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 84 | $86,605 |
| Merck | 33 | $21,164 |
| Johnson & Johnson | 4 | $4,482 |
| Medical Device Business Services, Inc. | 8 | $1,274 |
| Intuitive Surgical | 3 | $1,050 |
| AstraZeneca | 16 | $730 |
| Baxter Healthcare | 5 | $497 |
| Seagen Inc. | 3 | $157 |
| Pfizer | 2 | $144 |
| GSK | 4 | $115 |
| AbbVie | 3 | $76 |
| Astellas Pharma US Inc | 2 | $40 |
| Novartis | 1 | $31 |
| Solventum Corporation | 1 | $27 |
| Integra Lifesciences Corporation | 1 | $27 |
| Caris MPI, Inc. | 1 | $17 |
| LSI Solutions Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$85,740
- KEYTRUDA$20,621
- Harmonic$1,076
- DAVINCI XI$1,000
- TIVDAK$233
- LYNPARZA$232
- TISSEEL$212
- STARLING SYSTEM$138
- PerClot$129
- FLOSEAL$106
How this compares
$116,451 in reported general payments places this provider in the 90th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 27 | $1,153 |
| Olanzapine | 14 | $488 |
| Ondansetron Hcl | 13 | $254 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $121 |
| Oxycodone Hcl | 11 | $94 |
| Tramadol Hcl | 38 | $78 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Atlanta
- Benedict BenignoAtlanta$273K
- Gerald FeuerAtlanta$102K
- Guilherme CantuariaAtlanta$13K
- Cyril SpannAtlanta$12K
- Kevin AultAtlanta$10K
- Leda GattocAtlanta$7K
- Jennifer ScaliciAtlanta$6K
- Oi Wah YapAtlanta$3K
- Namita KhannaAtlanta$3K
- Joseph BoveriAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.